<tr id='qo26h'><strong id='qo26h'></strong><small id='qo26h'></small><button id='qo26h'></button><li id='qo26h'><noscript id='qo26h'><big id='qo26h'></big><dt id='qo26h'></dt></noscript></li></tr><ol id='qo26h'><option id='qo26h'><table id='qo26h'><blockquote id='qo26h'><tbody id='qo26h'></tbody></blockquote></table></option></ol><u id='qo26h'></u><kbd id='qo26h'><kbd id='qo26h'></kbd></kbd>
阿斯利康(kang)安達唐(通(tong)用名：達格列凈，一種鈉(na)-葡萄糖協同轉運蛋(dan)白-2 [SGLT2] 抑制劑)慢(man)性腎(shen)臟病(bing)適應癥在中(zhong)國獲批，用于降低有進展風險的慢(man)性腎(shen)臟病(bing)成人(ren)患(huan)者的估算腎(shen)小(xiao)球(qiu)濾過率(eGFR)持續下降、終末期腎(shen)病(bing)、心血管死(si)亡和因(yin)心力(li)衰竭而住院的風險。(醫藥健聞)
<small id='qo26h'></small><noframes id='qo26h'>
<tbody id='qo26h'></tbody>
<bdo id='qo26h'></bdo><ul id='qo26h'></ul>
